An audit of the use of hydroxychloroquine in rheumatology clinics.

Claudia WorthImran H YusufBethany TurnerHanae GourierEmma E BrooksDaniel O MortSrilakshmi SharmaSusan M DownesRaashid A Luqmani

Published in: Rheumatology advances in practice (2018)

HCQ therapy is being used for >5 years in 29% of patients with rheumatic diseases, with higher than recommended doses in ∼10% of patients. We recommend more rigorous scrutiny of the use of HCQ to reduce the risk of retinopathy.

Keyphrases

end stage renal disease
newly diagnosed
primary care
prognostic factors
stem cells
rheumatoid arthritis
mesenchymal stem cells
disease activity